Silvia Di Legge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Silvia Di Legge has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Paolo Stanzione
University of Rome Tor Vergata
10 shared publicationsFabrizio Sallustio
Department of Neuroscience, Tor Vergata University, Rome, Italy
7 shared publications- Fabrizio Sallustio
Stroke Unit, Department of Neuroscience, University of Tor Vergata, Rome, Italy
6 shared publications Vladimir Hachinski
5 shared publicationsGian Luigi Lenzi
University of Rome “La Sapienza
4 shared publications- Marina Diomedi
Stroke Center, Department of Systems Medicine, University of Rome Tor Vergata, Italy (I.M., M. Diomedi, G.L.).
4 shared publications
Latest Publications
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218515
Levodopa Use and Characteristics of Freezing-of-Gait in Patients With Parkinson Disease in the NS-Park and PPMI Cohorts
Background and ObjectivesRecent reports have suggested that levodopa exposure may contribute to freezing of gait (FOG), but this relationship remains controversial because of confounding by disease...
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218515
Levodopa Use and Characteristics of Freezing-of-Gait in Patients With Parkinson Disease in the NS-Park and PPMI Cohorts
Background and ObjectivesRecent reports have suggested that levodopa exposure may contribute to freezing of gait (FOG), but this relationship remains controversial because of confounding by disease...
- 6 September 2023
- Published by Elsevier in Pratique Neurologique - FMC
- Vol. 14 (3) , 132-149
Démarche diagnostique générale devant un patient présentant des mouvements anormaux : importance des examens biologiques dans cette stratégie
- 6 September 2023
- Published by Elsevier in Pratique Neurologique - FMC
- Vol. 14 (3) , 132-149
Démarche diagnostique générale devant un patient présentant des mouvements anormaux : importance des examens biologiques dans cette stratégie
- 14 September 2015
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 20 (6) , 211-212
The success of mechanical thrombectomy in acute ischaemic stroke is strictly dependent on ischaemic core size and time to treatment
Three trials showing no difference in clinical outcome between patients with acute ischaemic stroke (AIS) treated by mechanical thrombectomy (MT) and those treated by intravenous thrombolysis (IVT) had the effect of reducing the number of patients with AIS receiving endovascular therapy.1–4 Based on the enthusiasm of recent positive findings from the MR CLEAN,5 ESCAPE6 and EXTEND-IA7 trials, the REVASCAT and SWIFT PRIME trials have been stopped prematurely due to their positive findings and their results were released in April 2015. In both studies, MT was performed with the Solitaire revascularisation device, a self-expanding stent used to retrieve thrombi and restore blood flow, showing faster and higher rate of reperfusion, lower intracranial haemorrhage and better outcomes.8
- 14 September 2015
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 20 (6) , 211-212
The success of mechanical thrombectomy in acute ischaemic stroke is strictly dependent on ischaemic core size and time to treatment
Three trials showing no difference in clinical outcome between patients with acute ischaemic stroke (AIS) treated by mechanical thrombectomy (MT) and those treated by intravenous thrombolysis (IVT) had the effect of reducing the number of patients with AIS receiving endovascular therapy.1–4 Based on the enthusiasm of recent positive findings from the MR CLEAN,5 ESCAPE6 and EXTEND-IA7 trials, the REVASCAT and SWIFT PRIME trials have been stopped prematurely due to their positive findings and their results were released in April 2015. In both studies, MT was performed with the Solitaire revascularisation device, a self-expanding stent used to retrieve thrombi and restore blood flow, showing faster and higher rate of reperfusion, lower intracranial haemorrhage and better outcomes.8
- 25 February 2014
- Published by Springer Nature in La radiologia medica
- Vol. 119 (10) , 767-774
Efficacy of systemic thrombolysis within 4.5 h from stroke symptom onset: a single-centre clinical and diffusion–perfusion 3T MRI study
The efficacy of thrombolytic treatment with recombinant tissue plasminogen activator (rt-PA) within 3 h from stroke onset has been extensively supported by randomised placebo-controlled multicentre trials. In our single-centre study, we investigated the efficacy of intravenous (IV) administration of rt-PA within 4.5 h of stroke onset, in terms of clinical and radiological outcome, using a 3T magnetic resonance (MR) scanner in a cohort of patients similar to that of multicentre clinical trials. Consecutive patients treated with IV rt-PA were compared with an historical cohort of untreated patients (controls). Inclusion criteria were: (1) infarction of the middle cerebral artery territory, (2) eligibility for IV rt-PA treatment, and (3) 3T perfusion- and diffusion-weighted MR imaging and MR angiography performed within 4.5 h and repeated after 5–7 days. Stroke severity was assessed with the National Institutes of Health Stroke Scale (NIHSS). Growth of the DWI lesion, saved hypoperfused tissue, and clinical outcome was assessed and compared in treated patients and controls. Forty-three patients treated with rt-PA and 69 controls were eligible for the analysis. Treated patients showed higher percentages of saved hypoperfused tissue (75 vs. 40 %; p = 0.009), vessel recanalisation (65 vs. 27.5 %; p = 0.003), and haemorrhagic transformation (21 vs. 7 %; p = 0.004), without any clinically significant haemorrhages. Furthermore, treated patients had a significant improvement of NIHSS at 24 h (p p ≤0.001), and at the 3-month clinical evaluation (p p = 0.7). Treatment with IV rt-PA within 4.5 h of stroke onset preserves a significant amount of brain tissue from final infarction, and increases the possibility of early and late clinical improvement.
- 25 February 2014
- Published by Springer Nature in La radiologia medica
- Vol. 119 (10) , 767-774
Efficacy of systemic thrombolysis within 4.5 h from stroke symptom onset: a single-centre clinical and diffusion–perfusion 3T MRI study
The efficacy of thrombolytic treatment with recombinant tissue plasminogen activator (rt-PA) within 3 h from stroke onset has been extensively supported by randomised placebo-controlled multicentre trials. In our single-centre study, we investigated the efficacy of intravenous (IV) administration of rt-PA within 4.5 h of stroke onset, in terms of clinical and radiological outcome, using a 3T magnetic resonance (MR) scanner in a cohort of patients similar to that of multicentre clinical trials. Consecutive patients treated with IV rt-PA were compared with an historical cohort of untreated patients (controls). Inclusion criteria were: (1) infarction of the middle cerebral artery territory, (2) eligibility for IV rt-PA treatment, and (3) 3T perfusion- and diffusion-weighted MR imaging and MR angiography performed within 4.5 h and repeated after 5–7 days. Stroke severity was assessed with the National Institutes of Health Stroke Scale (NIHSS). Growth of the DWI lesion, saved hypoperfused tissue, and clinical outcome was assessed and compared in treated patients and controls. Forty-three patients treated with rt-PA and 69 controls were eligible for the analysis. Treated patients showed higher percentages of saved hypoperfused tissue (75 vs. 40 %; p = 0.009), vessel recanalisation (65 vs. 27.5 %; p = 0.003), and haemorrhagic transformation (21 vs. 7 %; p = 0.004), without any clinically significant haemorrhages. Furthermore, treated patients had a significant improvement of NIHSS at 24 h (p p ≤0.001), and at the 3-month clinical evaluation (p p = 0.7). Treatment with IV rt-PA within 4.5 h of stroke onset preserves a significant amount of brain tissue from final infarction, and increases the possibility of early and late clinical improvement.
- Open Access
- 15 December 2011
- Published by Wiley in ISRN Neurology
- Vol. 2011, 1-6
Short-Term and Two-Year Rate of Recurrent Cerebrovascular Events in Patients with Acute Cerebral Ischemia of Undetermined Aetiology, with and without a Patent Foramen Ovale
Purpose. We investigated stroke recurrence in patients with acute ischemic stroke of undetermined aetiology, with or without a patent foramen ovale (PFO). Methods. Consecutive stroke patients underwent to Transcranial Doppler and Transesophageal Echocardiography for PFO detection. Secondary stroke prevention was based on current guidelines. Results. PFO was detected in 57/129 (44%) patients. The rate of recurrent stroke did not significantly differ between patients with and without a PFO: 0.0% versus 1.4% (1 week), 1.7% versus 2.7% (1 month), and 3.5% versus 4.2% (3 months), respectively. The 2-year rates were 10.4% (5/48) in medically treated PFO and 8.3% (6/72) in PFO-negative patients (), with a relative risk of 1.25. No recurrent events occurred in 9 patients treated with percutaneous closure of PFO. Conclusion. PFO was not associated with increased rate of recurrent stroke. Age-related factors associated with stroke recurrence in cryptogenic stroke should be taken into account when patients older than 55 years are included in PFO studies.
- 15 December 2011
- Published by Wiley in ISRN Neurology
- Vol. 2011, 1-6
Open AccessShort-Term and Two-Year Rate of Recurrent Cerebrovascular Events in Patients with Acute Cerebral Ischemia of Undetermined Aetiology, with and without a Patent Foramen Ovale
Purpose. We investigated stroke recurrence in patients with acute ischemic stroke of undetermined aetiology, with or without a patent foramen ovale (PFO). Methods. Consecutive stroke patients underwent to Transcranial Doppler and Transesophageal Echocardiography for PFO detection. Secondary stroke prevention was based on current guidelines. Results. PFO was detected in 57/129 (44%) patients. The rate of recurrent stroke did not significantly differ between patients with and without a PFO: 0.0% versus 1.4% (1 week), 1.7% versus 2.7% (1 month), and 3.5% versus 4.2% (3 months), respectively. The 2-year rates were 10.4% (5/48) in medically treated PFO and 8.3% (6/72) in PFO-negative patients (), with a relative risk of 1.25. No recurrent events occurred in 9 patients treated with percutaneous closure of PFO. Conclusion. PFO was not associated with increased rate of recurrent stroke. Age-related factors associated with stroke recurrence in cryptogenic stroke should be taken into account when patients older than 55 years are included in PFO studies.
- Open Access
- 1 September 2011
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 32 (3) , 296-297
Effect of a Single Oral Dose of Sildenafil on Right-to-Left Shunt
- 1 September 2011
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 32 (3) , 296-297
Open AccessEffect of a Single Oral Dose of Sildenafil on Right-to-Left Shunt
- Open Access
- 8 August 2011
- Published by Wiley in Stroke Research and Treatment
- Vol. 2012, 1-5
Safety of Early Carotid Artery Stenting after Systemic Thrombolysis: A Single Center Experience
Background. Patients with acute ischemic stroke due to internal carotid artery (ICA) disease are at high risk of early stroke recurrence. A combination of IV thrombolysis and early carotid artery stenting (CAS) may result in more effective secondary stroke prevention.Objective. We tested safety and durability of early CAS following IV thrombolysis in stroke patients with residual stenosis in the symptomatic ICA.Methods. Of consecutive patients treated with IV rtPA, those with residual ICA stenosis ≥70% or 24 hours). The protocol included pre-rtPA MRI and MR angiography, and post-rtPA carotid ultrasound and CT angiography. Stroke severity was assessed by the NIH Stroke Scale (NIHSS). Three- and twelve-month stent patency was assessed by ultrasound. Twelve-month functional outcome was assessed by the modified Rankin Scale (mRS).Results. Of 145 consecutive IV rtPA-treated patients, 6 (4%) underwent early CAS. Median age was 76 (range 67–78) years, median NIHSS at stroke onset was 12 (range 9–16) and 7 (range 7-8) before CAS. Median onset-to-CAS time was 48 (range 30–94) hours. A single self-expandable stent was implanted to cover the entire lesion in all patients. The procedure was uneventful in all patients. After 12 months, all patients had stent patency, and the functional outcome was favourable (mRS ≤ 2) in all but 1 patient experiencing a recurrent stroke for new-onset atrial fibrillation.Conclusion. This small case series of a single centre suggests that early CAS may be considered a safe alternative to CEA after IV rtPA administration in selected patients at high risk of stroke recurrence.
- 8 August 2011
- Published by Wiley in Stroke Research and Treatment
- Vol. 2012, 1-5
Open AccessSafety of Early Carotid Artery Stenting after Systemic Thrombolysis: A Single Center Experience
Background. Patients with acute ischemic stroke due to internal carotid artery (ICA) disease are at high risk of early stroke recurrence. A combination of IV thrombolysis and early carotid artery stenting (CAS) may result in more effective secondary stroke prevention.Objective. We tested safety and durability of early CAS following IV thrombolysis in stroke patients with residual stenosis in the symptomatic ICA.Methods. Of consecutive patients treated with IV rtPA, those with residual ICA stenosis ≥70% or 24 hours). The protocol included pre-rtPA MRI and MR angiography, and post-rtPA carotid ultrasound and CT angiography. Stroke severity was assessed by the NIH Stroke Scale (NIHSS). Three- and twelve-month stent patency was assessed by ultrasound. Twelve-month functional outcome was assessed by the modified Rankin Scale (mRS).Results. Of 145 consecutive IV rtPA-treated patients, 6 (4%) underwent early CAS. Median age was 76 (range 67–78) years, median NIHSS at stroke onset was 12 (range 9–16) and 7 (range 7-8) before CAS. Median onset-to-CAS time was 48 (range 30–94) hours. A single self-expandable stent was implanted to cover the entire lesion in all patients. The procedure was uneventful in all patients. After 12 months, all patients had stent patency, and the functional outcome was favourable (mRS ≤ 2) in all but 1 patient experiencing a recurrent stroke for new-onset atrial fibrillation.Conclusion. This small case series of a single centre suggests that early CAS may be considered a safe alternative to CEA after IV rtPA administration in selected patients at high risk of stroke recurrence.
- 1 August 2011
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 12 (8) , 530-537
Cryptogenic cerebral ischemia
Objectives Paradoxical thromboembolism across a patent foramen ovale (PFO) may be involved in the pathogenesis of cryptogenic strokes. We tested the feasibility and the clinical usefulness of an early screening for PFO combining different ultrasound techniques in patients with acute cerebral ischemia of undetermined cause. Methods Consecutive patients with acute ischemic stroke or transient ischemic attack with undetermined cause were selected. Contrast-enhanced transcranial Doppler ultrasound (c-TCD) for detection of right-to-left shunt was performed on admission. Patients with right-to-left shunt on c-TCD underwent contrast-enhanced transesophageal echocardiography (c-TEE) and/or contrast-enhanced transthoracic echocardiography (c-TTE) for PFO confirmation. We tested the feasibility of this ultrasound algorithm in patients with acute cerebral ischemia, as well as its impact on further treatment decision. Results Over 30 months, we admitted 154 of 674 (23%) patients with undetermined stroke cause. Right-to-left shunt was detected by c-TCD in 76 of 148 (51%) patients. Of them, five of 76 (7%) patients dropped out of the study, whereas 10 of 76 (13%) could not perform a c-TEE due to lack of compliance. In the remaining 61 patients, a PFO was detected by c-TEE in 49 (80%) patients. Additional c-TTE study extended the examination for PFO detection to 66 patients, with a total of 57 PFO diagnosis (86%). An alternative stroke cause (i.e. an ulcerated aortic plaque) was detected in four patients. Conclusion A combined ultrasound approach based on a flexible diagnostic algorithm improved our ability to detect a PFO or alternative stroke cause in patients with acute cerebral ischemia of undetermined cause and to optimize secondary stroke prevention.
- 1 August 2011
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 12 (8) , 530-537
Cryptogenic cerebral ischemia
Objectives Paradoxical thromboembolism across a patent foramen ovale (PFO) may be involved in the pathogenesis of cryptogenic strokes. We tested the feasibility and the clinical usefulness of an early screening for PFO combining different ultrasound techniques in patients with acute cerebral ischemia of undetermined cause. Methods Consecutive patients with acute ischemic stroke or transient ischemic attack with undetermined cause were selected. Contrast-enhanced transcranial Doppler ultrasound (c-TCD) for detection of right-to-left shunt was performed on admission. Patients with right-to-left shunt on c-TCD underwent contrast-enhanced transesophageal echocardiography (c-TEE) and/or contrast-enhanced transthoracic echocardiography (c-TTE) for PFO confirmation. We tested the feasibility of this ultrasound algorithm in patients with acute cerebral ischemia, as well as its impact on further treatment decision. Results Over 30 months, we admitted 154 of 674 (23%) patients with undetermined stroke cause. Right-to-left shunt was detected by c-TCD in 76 of 148 (51%) patients. Of them, five of 76 (7%) patients dropped out of the study, whereas 10 of 76 (13%) could not perform a c-TEE due to lack of compliance. In the remaining 61 patients, a PFO was detected by c-TEE in 49 (80%) patients. Additional c-TTE study extended the examination for PFO detection to 66 patients, with a total of 57 PFO diagnosis (86%). An alternative stroke cause (i.e. an ulcerated aortic plaque) was detected in four patients. Conclusion A combined ultrasound approach based on a flexible diagnostic algorithm improved our ability to detect a PFO or alternative stroke cause in patients with acute cerebral ischemia of undetermined cause and to optimize secondary stroke prevention.
- 1 April 2011
- Published by Wolters Kluwer Health in Stroke
- Vol. 42 (4)
Letter by Legge et al Regarding Article, “Safety of Intravenous Fibrinolysis in Imaging-Confirmed Single Penetrator Artery Infarcts”
- 1 April 2011
- Published by Wolters Kluwer Health in Stroke
- Vol. 42 (4)
Letter by Legge et al Regarding Article, “Safety of Intravenous Fibrinolysis in Imaging-Confirmed Single Penetrator Artery Infarcts”